AMANDA STOUT: Open Payments
NPI 1740931062 · LYKENS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 50 payments from 15 companies in 2025. Trend: 2023 $1,221 · 2024 $1,171 · 2025 $914
Food & beverage: $914
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 13 | $199 |
| Novo Nordisk Inc | 7 | $124 |
| ABBVIE INC. | 4 | $92 |
| Lilly USA, LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| SANOFI-AVENTIS U.S. LLC | 1 | $26 |
Products named: REXULTI, NURTEC ODT, PAXLOVID, CAPLYTA, QULIPTA, SHINGRIX, JARDIANCE, Ozempic.
Industry payments across PA — which companies pay providers there.
